Is Telix Pharmaceuticals Limited (NASDAQ:TLX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Telix Pharmaceuticals Limited at current levels.
Illuccix is throwing off real cash while a radiopharmaceutical pipeline nobody has fully modelled matures behind it.
Where TLX is headed
Telix in 2028 looks less like an Australian diagnostics minnow and more like a vertically integrated radiopharmaceutical business with three commercial products, a therapeutic franchise entering the market, and manufacturing capacity that competitors have to rent from them. Illuccix is already doing the heavy lifting, driving that 49% revenue growth and funding the pipeline. Gozellix layers on top as a next-gen PSMA-PET agent with better half-life economics for regional distribution. The prize is TLX591, the lutetium-labelled prostate therapy in Phase 3, which if it reads out cleanly against Pluvicto's real-world data puts Telix into a therapy market Novartis has already proven can do multi-billion in annual sales.
Read the full Compass Direction on TLX
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $10.42).
See the full TLX analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Telix Pharmaceuticals Limited (NASDAQ:TLX) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Telix Pharmaceuticals Limited at current levels. Illuccix is throwing off real cash while a radiopharmaceutical pipeline nobody has fully modelled matures behind it.
What is TLX's Compass Score?
Telix Pharmaceuticals Limited scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for TLX?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the TLX page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.